|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vitro</i> studies involving the silencing of RhoGDI1 or RhoGDI2 demonstrated a significant increase in the migratory and invasive ability of tumor cells upon the silencing of these genes.
|
28789355 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rho GDP dissociation inhibitor 2 (RhoGDI2) has been identified as a tumor suppressor gene for cellular migration and invasion.
|
25266803 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the mechanisms by which RhoGDI2 promotes tumor cell survival and metastasis remain unclear.
|
24585459 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Rho GDP dissociation inhibitor 2 (RhoGDI2) expression correlates with tumor growth, metastasis, and chemoresistance in gastric cancer.
|
24721928 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rho GDP dissociation inhibitor 2 (RhoGDI2) promotes tumor growth and malignant progression and enhances chemoresistance of gastric cancer.
|
24185104 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
With regard to outcome in relation to RhoGDI2-positivity, RhoGDI2-higher expression tumors had a significant correlation with superior relapse-free survival (RFS) time as compared to RhoGDI2-lower expression tumors in stage III CRC (log-rank test, P < 0.05).
|
21698524 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further analysis indicated that RhoGDI2 suppressed metastasis by altering inflammation in the tumor microenvironment.
|
22406535 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RhoGDI2 expression was correlated strongly with tumor size, differentiation, and Duke's stage (P < 0.05).
|
21861235 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent work from our laboratory suggests that RhoGDI2 expression potentially enhances resistance to cisplatin as well as promotes tumor growth and malignant progression in gastric cancer.
|
21986528 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, we suggested that RhoGDI2 could promote tumor growth and malignant progression in gastric cancer.
|
21752536 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rho GDP dissociation inhibitor 2 (RhoGDI2) has been identified as a regulator of Rho GTPases that play important roles in the development of numerous aspects of the malignant phenotype, including cell cycle progression, resistance to apoptotic stimuli, neovascularization, tumor cell motility, invasiveness, and metastasis.
|
20001211 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although diminished RhoGDI2 expression in tumors is associated with decreased patient survival, normal expression in some metastatic tumors led us to wonder whether other mechanisms regulate RhoGDI2 function.
|
19321744 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The forced expression of RhoGDI2 caused a significant increase in gastric cancer cell invasion in vitro, and tumor growth, angiogenesis, and metastasis in vivo, whereas RhoGDI2 depletion evidenced opposite effects.
|
19351766 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2.
|
16878152 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Levels of endothelin-1 (ET-1), a potent vasoconstrictor, were affected by both RhoGDI2 reconstitution and tumor stage.
|
16103083 |
2005 |